HomeAI · summaries
Storia in 2 fonti
Pharmalittle: We're reading about employer coverage of obesity drugs, another Sanofi setback, and more
More employers are planning to drop coverage of GLP-1 drugs for weight loss next year as increasing numbers of people take the medications
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
Pharmalittle: We're reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more
Lilly disclosed new data that provide more details on the safety and tolerability of its next-generation obesity drug retatrutide
- ·
Pharmalittle: We're reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more
GSK agreed to buy Nuvalent, a cancer drug developer, in a deal worth $10.6 billion, as the company continues its expansion in oncology
